People in England to benefit from groundbreaking one-off gene therapy for severe sickle cell disease approved by NICE ...

The treatment is recommended for people aged 12 to 65 who have moderate to severe and persistent allergic rhinitis and have been diagnosed through clinical history and a positive test of their house ...

New and innovative mechanisms of action are constantly being discovered and developed into medicines that tackle a broad ...

NICE, in collaboration with other international health technology assessment agencies, has published a new report which ...

This indicator covers the incidence of healthcare associated infections from Methicillin-resistant Staphylococcus aureus (MRSA). It measures outcomes that reflect the quality of care or processes ...

This indicator covers under 75 mortality from respiratory disease. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator will be ...

This indicator will be reviewed using the assessment criteria in appendix B of the NICE indicators process guide when it reaches its review date or the underlying guidance is updated.

Proposed changes to appeal period for technology appraisal and highly specialised technologies appeals Methods / process manual consultation NICE process and methods 16 February 2025 Spesolimab for ...

For a short explanation of why the committee made this recommendation for research, see the rationale section on treatment strategies for non-proliferative and proliferative diabetic retinopathy .

This procedure should only be done as part of a formal research study, with NHS research ethics committee approval.

For a short explanation of why the committee made this recommendation for research, see the rationale section on information that should be available to all people involved in the care of people with ...

What are the clinical features or factors that suggest treatment should be switched or stopped for people with diabetic macular oedema? For a short explanation of why the committee made this ...